These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 712064)
21. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant. Nagase F; Ueda K; Kawashima K; Jamshedur Rahman SM; Isobe K; Yoshida T; Hasegawa Y; Ando K; Iwamoto T; Nagura E J Immunol; 1987 Apr; 138(7):2359-65. PubMed ID: 2951438 [TBL] [Abstract][Full Text] [Related]
22. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A. Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001 [TBL] [Abstract][Full Text] [Related]
23. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. Bright RK; Shearer MH; Kennedy RC J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411 [TBL] [Abstract][Full Text] [Related]
24. B lymphocyte regulation of the immune system. I. In vivo biologic activity of the novel lymphokine, B cell-derived enhancing factor (BEF). del Guercio P; del Guercio MF; Katz DH J Immunol; 1985 Feb; 134(2):996-1002. PubMed ID: 3871223 [TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline. Testorelli C; Archetti YL; Aresca P; Del Vecchio L Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006 [TBL] [Abstract][Full Text] [Related]
26. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice. Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042 [TBL] [Abstract][Full Text] [Related]
27. Cytophilic antibody as an auxiliary factor in cell-mediated immunity. Ptak W Allerg Immunol (Leipz); 1973; 19(2-4):290-6. PubMed ID: 4375939 [No Abstract] [Full Text] [Related]
28. In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice. Powderly WG; Pier GB; Markham RB J Immunol; 1987 Apr; 138(7):2272-7. PubMed ID: 2951437 [TBL] [Abstract][Full Text] [Related]
29. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210. Steele JK; Singhai R; Stammers AT; Levy JG J Immunol; 1986 Nov; 137(9):3025-30. PubMed ID: 3489783 [TBL] [Abstract][Full Text] [Related]
30. Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities. Stitz L; Baenziger J; Pircher H; Hengartner H; Zinkernagel RM J Immunol; 1986 Jun; 136(12):4674-80. PubMed ID: 3486908 [TBL] [Abstract][Full Text] [Related]
31. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Fuji H; Iribe H Cancer Res; 1986 Nov; 46(11):5541-7. PubMed ID: 3489524 [TBL] [Abstract][Full Text] [Related]
32. Analysis of the idiotypic network in tumor immunity. Raychaudhuri S; Saeki Y; Chen JJ; Kohler H J Immunol; 1987 Dec; 139(11):3902-10. PubMed ID: 2824616 [TBL] [Abstract][Full Text] [Related]
33. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor. Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733 [TBL] [Abstract][Full Text] [Related]
34. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice. Berd DA; Mitchell MS Cancer Res; 1976 Nov; 36(11 Pt 1):4119-24. PubMed ID: 975053 [TBL] [Abstract][Full Text] [Related]
35. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. Takatsuki F; Okano A; Suzuki C; Chieda R; Takahara Y; Hirano T; Kishimoto T; Hamuro J; Akiyama Y J Immunol; 1988 Nov; 141(9):3072-7. PubMed ID: 2459240 [TBL] [Abstract][Full Text] [Related]
36. Induction of immune resistance against L1210 lymphatic leukemia in mice after chemoradiotherapy of the leukemia and reconstitution with bone marrow purged from the leukemia with mafosfamide. Skórski T; Kawalec M Exp Hematol; 1988 Oct; 16(9):782-4. PubMed ID: 3049130 [TBL] [Abstract][Full Text] [Related]
37. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo. Yoshioka T; Sato S; Fujiwara H; Hamaoka T Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429 [TBL] [Abstract][Full Text] [Related]
38. Production of antibodies against ML antigen in the xenogeneic host. Radzikowski C; Zak-Nejmark T; Wysocka M; Steuden J Arch Immunol Ther Exp (Warsz); 1977; 25(4):507-13. PubMed ID: 931552 [TBL] [Abstract][Full Text] [Related]
39. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295 [TBL] [Abstract][Full Text] [Related]
40. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells. Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]